Novo Nordisk shares tumbled 23 per cent, their biggest one-day fall in 22 years, after a trial of its weight-loss drug CagriSema fell short of expectations.
2024-12-20 11:00:02
Novo Nordisk shares tumbled 23 per cent, their biggest one-day fall in 22 years, after a trial of its weight-loss drug CagriSema fell short of expectations.
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
